Averica Discovery appoints Cynthia Berger as Vice President of Operations

Will contribute broadly to the firm's growth and development

Averica Discovery, an analytical development contract research organisation (CRO) with specialised expertise in small molecule analysis and purification, has appointed Cynthia Berger to the newly-created position of Vice President of Operations.In her new role, Berger will report to CEO Jeff Kiplinger, and is expected to contribute broadly to the Massachusetts-based firm's growth and development.

Prior to joining Averica Discovery, Berger was project manager at PCI Synthesis, a contract manufacturing organisation (CMO), where she managed multimillion dollar projects manufacturing active pharmaceutical ingredients.

Previously, she was Vice President and a co-founder of Pion, an instrumentation company and CRO, where she developed and grew markets for instrumentation, established a contract research laboratory, and led the sale of the company to a private investment group.

You may also like

Research & Development

Canadian-based Neopharm Labs completes acquisition of Boston-based Averica Discovery Services

The combined expertise creates a key player in the North American analytical market
Regulatory

Averica now able to handle Schedule I controlled substances

And expand the types of research that the company can support
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Hybrid interferons: developing a novel drug class

With many hurdles to overcome, establishing a new drug candidate is a long process — particularly if you are a smaller biotech company with limited resources. These challenges can be further amplified if the candidate being developed is of an entirely novel drug class
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Manufacturing

Anton Paar expands Litesizer DIA Series with new models

Introducing affordable and advanced solutions for particle analysis
Manufacturing

Triple your efficiency with the new DrySyn Vortex

Boost productivity with temperature-controlled parallel reactions
Subscribe now